{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T07:26:53Z","timestamp":1767857213555,"version":"3.49.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T00:00:00Z","timestamp":1735171200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009634","name":"Susan G. Komen","doi-asserted-by":"publisher","award":["TREND21675016"],"award-info":[{"award-number":["TREND21675016"]}],"id":[{"id":"10.13039\/100009634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R56CA282891"],"award-info":[{"award-number":["R56CA282891"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R33 CA269100"],"award-info":[{"award-number":["R33 CA269100"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01 CA280637"],"award-info":[{"award-number":["R01 CA280637"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01CA223662"],"award-info":[{"award-number":["R01CA223662"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.bneo.2024.100065","type":"journal-article","created":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T17:31:01Z","timestamp":1735234261000},"page":"100065","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Population differences in the associations between chromosomal abnormalities and overall survival of multiple myeloma"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3125-5140","authenticated-orcid":false,"given":"Bei","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4070-1819","authenticated-orcid":false,"given":"Benjamin A.","family":"Derman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1843-7038","authenticated-orcid":false,"given":"Madina","family":"Sukhanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2362-6391","authenticated-orcid":false,"given":"Daniel","family":"Appelbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2131-1767","authenticated-orcid":false,"given":"John","family":"Cursio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Jakubowiak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8979-7244","authenticated-orcid":false,"given":"Brian C.-H.","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bneo.2024.100065_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"10.1016\/j.bneo.2024.100065_bib2","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-020-00359-2","article-title":"Multiple myeloma current treatment algorithms","volume":"10","author":"Rajkumar","year":"2020","journal-title":"Blood Cancer J"},{"issue":"25","key":"10.1016\/j.bneo.2024.100065_bib4","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1182\/blood-2010-07-298760","article-title":"Racial disparities in incidence and outcome in multiple myeloma: a population-based study","volume":"116","author":"Waxman","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bneo.2024.100065_bib5","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/bloodadvances.2016002493","article-title":"Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States","volume":"1","author":"Costa","year":"2017","journal-title":"Blood Adv"},{"issue":"24","key":"10.1016\/j.bneo.2024.100065_bib6","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1182\/blood.2019000406","article-title":"With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study","volume":"133","author":"Fillmore","year":"2019","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bneo.2024.100065_bib7","doi-asserted-by":"crossref","first-page":"e506","DOI":"10.1016\/j.clml.2019.04.019","article-title":"Superior survival in African American patients who underwent autologous stem cell transplantation for multiple myeloma","volume":"19","author":"Sweiss","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"24","key":"10.1016\/j.bneo.2024.100065_bib8","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1002\/cncr.34479","article-title":"Annual report to the nation on the status of cancer, part 1: national cancer statistics","volume":"128","author":"Cronin","year":"2022","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.bneo.2024.100065_bib9","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41571-018-0018-y","article-title":"The multiple myelomas \u2014 current concepts in cytogenetic classification and therapy","volume":"15","author":"Kumar","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"10.1016\/j.bneo.2024.100065_bib10","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1001\/jamaoncol.2016.5763","article-title":"Diagnosis and management of Waldenstr\u00f6m macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines 2016","volume":"3","author":"Kapoor","year":"2017","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.bneo.2024.100065_bib11","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1182\/asheducation-2017.1.115","article-title":"Novel approaches to therapy in CML","volume":"2017","author":"Bhatia","year":"2017","journal-title":"Hematology"},{"issue":"1","key":"10.1016\/j.bneo.2024.100065_bib12","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/ajh.24607","article-title":"Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management","volume":"92","author":"Tefferi","year":"2017","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.bneo.2024.100065_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.92","article-title":"Interpretation of cytogenetic results in multiple myeloma for clinical practice","volume":"5","author":"Rajan","year":"2015","journal-title":"Blood Cancer J"},{"issue":"8","key":"10.1016\/j.bneo.2024.100065_bib14","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41408-020-00348-5","article-title":"Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response","volume":"10","author":"Abdallah","year":"2020","journal-title":"Blood Cancer J"},{"issue":"8","key":"10.1016\/j.bneo.2024.100065_bib15","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1182\/blood-2005-04-1411","article-title":"Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy","volume":"106","author":"Gertz","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bneo.2024.100065_bib16","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/sj.leu.2404516","article-title":"A\u00a0practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy","volume":"21","author":"Stewart","year":"2007","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.bneo.2024.100065_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.6","article-title":"(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs","volume":"5","author":"Narita","year":"2015","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1016\/j.bneo.2024.100065_bib18","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-019-0254-0","article-title":"Gain of chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone","volume":"9","author":"Schmidt","year":"2019","journal-title":"Blood Cancer J"},{"issue":"24","key":"10.1016\/j.bneo.2024.100065_bib19","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2024.100065_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2014.91","article-title":"Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study","volume":"5","author":"Greenberg","year":"2015","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.bneo.2024.100065_bib21","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41408-018-0132-1","article-title":"Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestry","volume":"8","author":"Baughn","year":"2018","journal-title":"Blood Cancer J"},{"issue":"21","key":"10.1016\/j.bneo.2024.100065_bib22","doi-asserted-by":"crossref","first-page":"5331","DOI":"10.3390\/cancers14215331","article-title":"Body mass index and overall survival of patients with newly diagnosed multiple myeloma","volume":"14","author":"Wang","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.bneo.2024.100065_bib23","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13045-022-01327-y","article-title":"Genome-wide profiling of 5-hydroxymethylcytosines in circulating cell-free DNA reveals population-specific pathways in the development of multiple myeloma","volume":"15","author":"Chiu","year":"2022","journal-title":"J\u00a0Hematol Oncol"},{"issue":"12","key":"10.1016\/j.bneo.2024.100065_bib24","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bneo.2024.100065_bib25","series-title":"ISCN 2016: An International System for Human Cytogenomic Nomenclature (2016)","author":"McGowan-Jordan","year":"2016"},{"issue":"6","key":"10.1016\/j.bneo.2024.100065_bib26","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A\u00a0More accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.bneo.2024.100065_bib27","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk-stratification and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.bneo.2024.100065_bib28","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.beha.2005.01.012","article-title":"Prognostic features of multiple myeloma","volume":"18","author":"San Miguel","year":"2005","journal-title":"Best Pract Res Clin Haematol"},{"issue":"12","key":"10.1016\/j.bneo.2024.100065_bib29","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/leu.2009.174","article-title":"International Myeloma Working Group molecular classification of multiple myeloma: spotlight review","volume":"23","author":"Fonseca","year":"2009","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.bneo.2024.100065_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-020-00347-6","article-title":"Racial differences in treatment and outcomes in multiple myeloma: a Multiple Myeloma Research Foundation analysis","volume":"10","author":"Derman","year":"2020","journal-title":"Blood Cancer J"},{"issue":"26","key":"10.1016\/j.bneo.2024.100065_bib31","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.bneo.2024.100065_bib32","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/leu.2013.247","article-title":"IMWG consensus on risk stratification in multiple myeloma","volume":"28","author":"Chng","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.bneo.2024.100065_bib33","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41408-022-00679-5","article-title":"High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions","volume":"12","author":"Hagen","year":"2022","journal-title":"Blood Cancer J"},{"issue":"11","key":"10.1016\/j.bneo.2024.100065_bib34","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1038\/sj.leu.2404403","article-title":"Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma","volume":"20","author":"Fonseca","year":"2006","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.bneo.2024.100065_bib35","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s12185-022-03353-5","article-title":"Multiple myeloma with high-risk cytogenetics and its treatment approach","volume":"115","author":"Hanamura","year":"2022","journal-title":"Int J Hematol"},{"issue":"21","key":"10.1016\/j.bneo.2024.100065_bib36","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1182\/blood.V116.21.305.305","article-title":"Bortezomib-based induction therapy followed by autologous stem cell transplantation and maintenance therapy with bortezomib improves outcome in myeloma patients with gain 1q21 and t(4;14) - a subgroup analysis of the HOVON-65\/GMMG-HD4 trial","volume":"116","author":"Goldschmidt","year":"2010","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.bneo.2024.100065_bib37","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2012.48.4626","article-title":"Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials","volume":"31","author":"Sonneveld","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.bneo.2024.100065_bib38","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/OP.22.00781","article-title":"Impact of black race on peripheral neuropathy in patients with newly diagnosed multiple myeloma receiving bortezomib induction","volume":"19","author":"Sun","year":"2023","journal-title":"JCO Oncol Pract"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2024.100065_bib39","first-page":"5436","article-title":"Impact of race on bortezomib-induced peripheral neuropathy","volume":"130","author":"Cheung","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bneo.2024.100065_bib43","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.83","article-title":"Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma","volume":"7","author":"Binder","year":"2017","journal-title":"Blood Cancer J"},{"issue":"13","key":"10.1016\/j.bneo.2024.100065_bib44","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1182\/blood-2014-07-587964","article-title":"Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience","volume":"125","author":"Hebraud","year":"2015","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.bneo.2024.100065_bib45","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1182\/blood-2012-07-443606","article-title":"Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach","volume":"121","author":"Baker","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bneo.2024.100065_bib46","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/bjh.13950","article-title":"Race-based differences in routine cytogenetic profiles of patients with multiple myeloma","volume":"176","author":"Blue","year":"2017","journal-title":"Br J Haematol"},{"issue":"15","key":"10.1016\/j.bneo.2024.100065_bib47","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1182\/blood.2021014309","article-title":"Guiding the global evolution of cytogenetic testing for hematologic malignancies","volume":"139","author":"Akkari","year":"2022","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bneo.2024.100065_bib48","doi-asserted-by":"crossref","first-page":"e1169","DOI":"10.1200\/JOP.19.00639","article-title":"Variability in cytogenetic testing for multiple myeloma: a comprehensive analysis from across the United States","volume":"16","author":"Yu","year":"2020","journal-title":"JCO Oncol Pract"},{"issue":"8","key":"10.1016\/j.bneo.2024.100065_bib49","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1038\/s41375-019-0378-z","article-title":"European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms","volume":"33","author":"Rack","year":"2019","journal-title":"Leukemia"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328024000657?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328024000657?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T05:00:27Z","timestamp":1745038827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328024000657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2950328024000657"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2024.100065","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population differences in the associations between chromosomal abnormalities and overall survival of multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2024.100065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100065"}}